• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Synopsys Inc.

    7/3/25 9:16:56 AM ET
    $SNPS
    Computer Software: Prepackaged Software
    Technology
    Get the next $SNPS alert in real time by email
    8-K
    SYNOPSYS INC false 0000883241 0000883241 2025-07-02 2025-07-02
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (date of earliest event reported): July 2, 2025

     

     

    SYNOPSYS, INC.

    (Exact name of registrant as specified in charter)

     

     

     

    Delaware   000-19807   56-1546236

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    675 Almanor Ave.

    Sunnyvale, California 94085

    (Address of principal executive offices) (Zip code)

    Registrant’s telephone number, including area code: (650) 584-5000

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock
    (par value of $0.01 per share)
      SNPS   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 8.01 Other Events

    On July 2, 2025, Synopsys received a letter from the Bureau of Industry and Security of the U.S. Department of Commerce informing Synopsys that the export restrictions related to China, pursuant to a letter received on May 29, 2025, have now been rescinded, effective immediately. Synopsys is working to restore access to the recently restricted products in China. Synopsys is continuing to assess the impact of export restrictions related to China on its business, operating results and financials.

    Cautionary Statement Regarding Forward-Looking Statements

    This Current Report on Form 8-K contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the restoration of access of Synopsys products to our customers in China and the potential impact of the export restrictions. These statements involve risks, uncertainties and other factors, including those factors listed in Synopsys’ most recent reports on Form 10-K and Form 10-Q, that could cause our actual results, time frames or achievements to differ materially from those expressed or implied in such forward-looking statements. The information provided herein is as of July 2, 2025. Synopsys undertakes no duty to, and does not intend to, update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

     

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

        SYNOPSYS, INC.
    Dated: July 3, 2025     By:  

    /s/ John F. Runkel, Jr.

                John F. Runkel, Jr.
                General Counsel and Corporate Secretary

     

    3

    Get the next $SNPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNPS

    DatePrice TargetRatingAnalyst
    1/13/2025$600.00Buy
    Redburn Atlantic
    11/22/2024$570.00Equal Weight
    Wells Fargo
    11/12/2024$675.00Buy
    Loop Capital
    10/22/2024$650.00Outperform
    Mizuho
    10/15/2024$660.00Buy
    Berenberg
    4/4/2024$665.00Overweight
    Piper Sandler
    11/30/2023$500.00 → $660.00Buy
    Needham
    11/10/2023$600.00Overweight
    Morgan Stanley
    More analyst ratings